Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU

Merck announced yesterday that new combination and monotherapy data from the company ’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.02/12/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news